VAG
UTHR icon

VisionPoint Advisory Group’s United Therapeutics UTHR Stock Holding History

VisionPoint Advisory Group’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$655K Sell
1,209
-32
-3% -$18K 0.11% 210
2026
Q1 		$736K Sell
1,241
-146
-11% -$72.7K 0.14% 170
2025
Q4 		$676K Buy
1,387
+238
+21% +$111K 0.13% 172
2025
Q3 		$482K Sell
1,149
-158
-12% -$53.1K 0.1% 212
2025
Q2 		$376K Buy
+1,307
New +$391K 0.08% 231

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

VisionPoint Advisory Group's UTHR Position: Q2 2026 in Review

VisionPoint Advisory Group reduced its United Therapeutics (UTHR) stake by 2.6% in Q2 2026, selling an estimated $18K and leaving 1,209 shares worth $655K. The position accounts for 0.11% of the portfolio, ranked #210.

VisionPoint Advisory Group first reported a position in UTHR in Q2 2025 and has held it in 5 quarters since. The position peaked at $736K in Q1 2026. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • VisionPoint Advisory Group held 1,209 shares of United Therapeutics worth $655K as of Q2 2026.
  • VisionPoint Advisory Group sold 32 United Therapeutics shares in Q2 2026, an estimated $18K.
  • United Therapeutics made up 0.11% of VisionPoint Advisory Group's portfolio in Q2 2026, its #210 holding.
  • VisionPoint Advisory Group first reported a position in United Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • VisionPoint Advisory Group's United Therapeutics position peaked at $736K in Q1 2026.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on VisionPoint Advisory Group's 13F filing for Q2 2026, filed 7 Jul 2026.